In the Absence of Renal Disease, 20 year Mortality Risk in Type 1 Diabetes is Comparable to That of the General Population: a Report from the Pittsburgh Epidemiology of Diabetes Complications Study
Overview
Authors
Affiliations
Aims/hypothesis: The FinnDiane Study has reported that mortality in type 1 diabetes is not increased over a 7 year follow-up in the absence of renal disease (RD). Using the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study population (n = 658) of childhood-onset type 1 diabetes (age <17 years), the present study sought to replicate and expand these findings to a 20 year follow-up (as of 1 January 2008) and examine cause of death by renal status.
Methods: At baseline (1986-1988), mean age and duration of diabetes were 28 and 19 years, respectively. RD was defined as an albumin excretion rate ≥20 μg/min from multiple samples and grouped as microalbuminuria (MA; 20-200 μg/min), overt nephropathy (ON; >200 μg/min), or end stage renal disease (ESRD; dialysis or renal transplantation).
Results: At baseline, 311 (47.3%) individuals had RD (MA 21.3%, ON 22.2% and ESRD 3.8%). During a median 20 year follow-up, there were 152 deaths (23.1%). Mortality was 6.2 (95% CI 5.2-7.2) times higher than expected, with standardised mortality ratios of 2.0 (1.2-2.8) for normoalbuminuria (NA); 6.4 (4.4-8.4) for MA; 12.5 (9.5-15.4) for ON; and 29.8 (16.8-42.9) for ESRD. Excluding those (n = 64) with NA who later progressed to RD, no significant excess mortality was observed in the remaining NA group (1.2, 0.5-1.9), whose deaths were largely unrelated to diabetes.
Conclusions/interpretation: These data confirm the importance of RD, including persistent microalbuminuria, as a marker of mortality risk and suggest that type 1 diabetes patients without renal disease achieve long-term survival comparable to the general population.
Narongkiatikhun P, Bjornstad P Kidney Int Rep. 2024; 9(12):3351-3354.
PMID: 39698361 PMC: 11652309. DOI: 10.1016/j.ekir.2024.10.010.
Fountoulakis N, Miyamoto Y, Pavkov M, Karalliedde J, Maltese G Diabet Med. 2024; 42(2):e15464.
PMID: 39497615 PMC: 11733662. DOI: 10.1111/dme.15464.
Kovacevic S, Zdravkovic V, Blagojevic J, Djordjevic S, Miolski J, Gasic V PLoS One. 2024; 19(10):e0312489.
PMID: 39446857 PMC: 11500908. DOI: 10.1371/journal.pone.0312489.
Limonte C, Lamprea-Montealegre J, Tuttle K Semin Nephrol. 2024; 44(2):151520.
PMID: 38705774 PMC: 11283968. DOI: 10.1016/j.semnephrol.2024.151520.
Methylglyoxal-Derived Nucleoside Adducts Drive Vascular Dysfunction in a RAGE-Dependent Manner.
Lai S, Bhattacharya S, Lopez Gonzalez E, Shuck S Antioxidants (Basel). 2024; 13(1).
PMID: 38247509 PMC: 10812505. DOI: 10.3390/antiox13010085.